Search Results - "van Heerde, Waander L."

Multicolor flow cytometry for evaluation of platelet surface antigens and activation markers by van Velzen, Jeroen F, Laros-van Gorkom, Britta A.P, Pop, Gheorghe A.M, van Heerde, Waander L

“…Abstract Introduction Flow cytometry allows the analysis of multiple antigens in a single tube at a single cell level. We present a rapid and sensitive two…”
Get full text

Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study by Willems, Sterre P.E., Simons, Annet, Saes, Joline L., Weiss, Marjan, Rijpma, Sanna, Schoormans, Selene, Meijer, Karina, Cnossen, Marjon H., Schutgens, Roger E.G., van Es, Nick, Nieuwenhuizen, Laurens, den Exter, Paul L., Kruis, Ilmar C., Blijlevens, Nicole M.A., van Heerde, Waander L., Schols, Saskia E.M.

“…Rare coagulation factor deficiencies and disorders of fibrinolysis (defined as rare bleeding disorders [RBDs]) present with a heterogeneous bleeding phenotype,…”
Get full text

The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A by Valke, Lars L.F.G., Verhagen, Marieke J.A., Mulders, Bart T.P.M., Polenewen, Robert, Blijlevens, Nicole M.A., Jansen, Joop H., Mansouritorghabeh, Hassan, Elsheikh, Einas, Reipert, Birgit M., Turecek, Peter L., O'Donnell, James S., Rijpma, Sanna R., Schols, Saskia E.M., van Heerde, Waander L., Meijer, Danielle

“…BACKGROUNDAn inhibitor can develop in congenital hemophilia A (HA) patients against exogenous infused factor (F)VIII, whereas in acquired HA (AHA) inhibitors…”
Get full text

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases by Valke, Lars L. F. G., Rijpma, Sanna, Meijer, Danielle, Schols, Saskia E. M., van Heerde, Waander L.

“…Treatment of bleeding and thrombotic disorders is highly standardized and based on evidence-based medicine guidelines. These evidence-based treatment schemes…”
Get full text

Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype by Atiq, Ferdows, Boender, Johan, Heerde, Waander L., Tellez Garcia, Juan M., Schoormans, Selene C., Krouwel, Sandy, Cnossen, Marjon H., Laros‐van Gorkom, Britta A. P., Meris, Joke, Fijnvandraat, Karin, Bom, Johanna G., Meijer, Karina, Galen, Karin P. M., Eikenboom, Jeroen, Leebeek, Frank W. G.

“…Genotyping is not routinely performed at diagnosis of von Willebrand disease (VWD). Therefore, the association between genetic variants and pathogenic…”
Get full text

A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis by van Geffen, Mark, Loof, Arnoud, Lap, Paul, Boezeman, Jan, Laros-van Gorkom, Britta A P, Brons, Paul, Verbruggen, Bert, van Kraaij, Marian, van Heerde, Waander L

“…Thrombin and plasmin are the key enzymes involved in coagulation and fibrinolysis. A novel hemostasis assay (NHA) was developed to measure thrombin and plasmin…”
Get more information

Polymorphisms in the Annexin A5 gene influence circulating Annexin A5 levels in healthy controls by Hiddink, Larissa, de Visser, Marieke C.H, van Heerde, Waander L

Get full text

Transient expression of phosphatidylserine at cell-cell contact areas is required for myotube formation by van den Eijnde, S M, van den Hoff, M J, Reutelingsperger, C P, van Heerde, W L, Henfling, M E, Vermeij-Keers, C, Schutte, B, Borgers, M, Ramaekers, F C

“…Cell surface exposure of phosphatidylserine (PS) is shown to be part of normal physiology of skeletal muscle development and to mediate myotube formation. A…”
Get full text

Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment by van Kuilenburg, Janet, MD, Lappegård, Knut Tore, MD, Sexton, Joe, PhD, Plesiewicz, Izabela, MD, Lap, Paul, PhD, Bouwels, Leon, MD, Sprong, Tom, MD, Mollnes, Tom Eirik, MD, PhD, Verheugt, Freek, MD, PhD, van Heerde, Waander L., PhD, Pop, Gheorghe A., MD, PhD

“…Background It has been demonstrated that the occurrence of ischemic stroke is more prevalent in AF patients, when increased levels of inflammatory markers are…”
Get full text

Activity Sensing of Coagulation and Fibrinolytic Proteases by Sondag, Daan, Verhoeven, Stijn, Löwik, Dennis W. P. M., Geffen, Mark, Veer, Cornelis van't, Heerde, Waander L., Boltje, Thomas J., Rutjes, Floris P. J. T.

“…The blood coagulation cascade is a complex physiological process involving the action of multiple coupled enzymes, cofactors, and substrates, ultimately…”
Get full text

Synthesis and Evaluation of Glycosyl Luciferins by Sondag, Daan, Kleijne, Frank F. J., Castermans, Sam, Chatzakis, Isa, Geffen, Mark, van't Veer, Cornelis, Heerde, Waander L., Boltje, Thomas J., Rutjes, Floris P. J. T.

“…Measuring glycosidase activity is important to monitor any aberrations in carbohydrate hydrolase activity, but also for the screening of potential glycosidase…”
Get full text

Frontispiece: Activity Sensing of Coagulation and Fibrinolytic Proteases by Sondag, Daan, Verhoeven, Stijn, Löwik, Dennis W. P. M., Geffen, Mark, Veer, Cornelis van't, Heerde, Waander L., Boltje, Thomas J., Rutjes, Floris P. J. T.

“…This work describes the main proteases present in the coagulation cascade and fibrinolytic processes and highlights existing strategies of sensing these…”
Get full text

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A by Eckhardt, Corien L., van Velzen, Alice S., Peters, Marjolein, Astermark, Jan, Brons, Paul P., Castaman, Giancarlo, Cnossen, Marjon H., Dors, Natasja, Escuriola-Ettingshausen, Carmen, Hamulyak, Karly, Hart, Daniel P., Hay, Charles R.M., Haya, Saturnino, van Heerde, Waander L., Hermans, Cedric, Holmström, Margareta, Jimenez-Yuste, Victor, Keenan, Russell D., Klamroth, Robert, Laros-van Gorkom, Britta A.P., Leebeek, Frank W.G., Liesner, Ri, Mäkipernaa, Anne, Male, Christoph, Mauser-Bunschoten, Evelien, Mazzucconi, Maria G., McRae, Simon, Meijer, Karina, Mitchell, Michael, Morfini, Massimo, Nijziel, Marten, Oldenburg, Johannes, Peerlinck, Kathelijne, Petrini, Pia, Platokouki, Helena, Reitter-Pfoertner, Sylvia E., Santagostino, Elena, Schinco, Piercarla, Smiers, Frans J., Siegmund, Berthold, Tagliaferri, Annarita, Yee, Thynn T., Kamphuisen, Pieter Willem, van der Bom, Johanna G., Fijnvandraat, Karin

“…Neutralizing antibodies (inhibitors) toward factor VIII form a severe complication in nonsevere hemophilia A, profoundly aggravating the bleeding pattern…”
Get full text

Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease by Verhagen, Marieke J A, van Balen, Erna C, Blijlevens, Nicole M A, Coppens, Michiel, van Heerde, Waander L, Leebeek, Frank W G, Rijpma, Sanna R, van Vulpen, Lize F D, Gouw, Samantha C, Schols, Saskia E M

“…Patients with moderate hemophilia express varying bleeding phenotypes. To assess the burden of disease in patients with moderate hemophilia and a mild or…”
Get full text

Global haemostasis assays, from bench to bedside by van Geffen, Mark, van Heerde, Waander L

“…Abstract Bleeding and thrombosis are the ultimate clinical outcomes of aberrations in the haemostatic process. Haemostasis prevents excessive blood loss due to…”
Get full text

Idiopathic factor VIII inhibitor autoantibody in a man presented after accident by Mansouritorghabeh, Hassan, Lak, Manijeh, van Heerde, Waander L

“…Acquired hemophilia A is a rare but severe autoimmune bleeding disorder caused by autoantibodies against factor VIII activity and is a potentially…”
Get more information

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study by Maas, Dominique P. M. S. M., Saes, Joline L., Blijlevens, Nicole M. A., Cnossen, Marjon H., den Exter, Paul L., Kruis, Ilmar C., Meijer, Karina, Nieuwenhuizen, Laurens, Peters, Marjolein, Schutgens, Roger E. G., Heerde, Waander L., Schols, Saskia E. M.

“…Background Patients with rare inherited bleeding disorders (RBDs) exhibit hemorrhagic symptoms, varying in type and severity, often requiring only on‐demand…”
Get full text

Solid-Phase Synthesis of Caged Luminescent Peptides via Side Chain Anchoring by Sondag, Daan, Heming, Jurriaan J. A., Löwik, Dennis W. P. M., Krivosheeva, Elena, Lejeune, Denise, van Geffen, Mark, van’t Veer, Cornelis, van Heerde, Waander L., Beens, Marjolijn C. J., Kuijpers, Brian H. M., Boltje, Thomas J., Rutjes, Floris P. J. T.

“…The synthesis of caged luminescent peptide substrates remains challenging, especially when libraries of the substrates are required. Most currently available…”
Get full text

Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study by van Kwawegen, Calvin B., Atiq, Ferdows, Endenburg, Dara, Fijnvandraat, Karin, van Galen, Karin P.M., Cnossen, Marjon H., Schols, Saskia E.M., Kruip, Marieke J.H.A., van Heerde, Waander L., de Meris, Joke, van der Bom, Johanna G., Eikenboom, Jeroen, Meijer, Karina, Leebeek, Frank W.G., Fijnvandraat, K., Coppens, M., Kors, A., Zweegman, S., de Meris, J., Goverde, G.J., Jonkers, M.H., Dors, N., Nijziel, M.R., Nieuwenhuizen, L., Meijer, K., Tamminga, R.Y.J., van der Linden, P.W., Ypma, P.F., Eikenboom, H.C.J., van der Bom, J.G., Smiers, F.J.W., Granzen, B., Hamulyák, K., Brons, P., Laros-van Gorkom, B.A.P., Schols, S.E.M., Leebeek, F.W.G., Cnossen, M.H., Boender, J., Atiq, F., van Kwawegen, C.B., Mauser-Bunschoten, E.P., van Galen, K.P.M.

“…Type 2B von Willebrand disease (VWD) is a bleeding disorder caused by gain-of-function variants in the VWF gene. The laboratory and clinical phenotype of type…”
Get full text

Von Willebrand disease type 2M: Correlation between genotype and phenotype: Reply to comment from Dr. Favaloro and to comment from Dr. Woods et al by Maas, Dominique P. M. S. M., Heerde, Waander L., Schols, Saskia E. M.

Get full text